This is a working overview of elevated plus maze, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or below | For lyophilized powder, long term |
| Common analytical method | Reverse-phase HPLC | Usually paired with mass spectrometry |
| Typical reported purity | At or above 95 percent by area | Research-grade material |
| Aqueous solubility | High | Solutions used in laboratory assays |
| Moisture sensitivity | Hydrolyzes in solution | Aseptic handling reduces degradation |
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
This suggests FEN1 suppresses H-DNA-induced mutagenesis in a replication-dependent manner. H-DNA has been implicated in human cancer etiology because of the prevalence of H-DNA-forming sequences near translocation breakpoints in cancer genomes. Replication-mediated nuclease activity with H-DNA highlights another way H-DNA-induced mutagenesis and lead to cancer growth.
=== Rheumasurgery === Rheumasurgery (or rheumatoid surgery) is a subfield of orthopedics occupied with the surgical treatment of patients with rheumatic diseases. The purpose of the interventions is to limit disease activity, soothe pain and improve function. Rheumasurgical interventions can be divided in two groups. The one is early synovectomies, that is the removal of the inflamed synovia in order to prevent spreading and stop destruction. The other group is the so-called corrective intervention, i.e. an intervention done after destruction has taken place. Among the corrective interventions are joint replacements, removal of loose bone or cartilage fragments, and a variety of interventions aimed at repositioning and/or stabilizing joints, such as arthrodesis.
== Contamination sources and removal == Bacteria, particles, organic carbon, ions, and dissolved gases are all present in typical municipal water systems and must be removed to create ultrapure water.
The filmmakers decided that Dredd should appear lean and fast like a boxer rather than bulky like "someone who spends hours sort of steroiding himself up." His Judge uniform was altered from the comic version; an extruded eagle statuette was removed from his shoulder pad to emphasise the outfit's functionality and give it a sense of realism. Garland said: "If you did a very faithful adaptation of the uniform you'd have someone who if he got stabbed in the stomach he'd be in big trouble. Dredd is out there on the frontline so he needed protection." Remaining faithful to the comic, Dredd's face, except for his mouth, is never shown and his helmet is not removed throughout the film. Urban said: "He is supposed to be the faceless representative of the law and I think that is part of his enigma ... You wouldn't get to the end of a Sergio Leone Western and go, 'God, I didn't even know the character's name!' It's irrelevant." Dredd's signature weapon, the "Lawgiver" was developed as a fully operational weapon based on a 9mm firing system, capable of firing ammunition and being changed from automatic to semi-auto fire. His motorcycle "Lawmaster" was a modified 500cc motorcycle. A large fairing was added over the motorcycle with machine guns, an extended wheel base and the largest functional tyres possible. The vehicle was also operational and Urban insisted on riding it himself rather than relying on green-screen visual effects.
on the toxicity findings of publicly-funded academics, whose methods are very heterogeneous, but who test, and often find, toxicity at much lower doses that industry's TG studies); or, a nation may interpret the accepted study's results according to its own criteria. According to OECD Council Decision C(97)186/Final, chemical testing data generated in any OECD member country following OECD Test Guidelines and GLP principles is recognized by other OECD member countries, such as Australia, Canada, Korea, and the USA. This recognition also extends to some non-OECD countries that fully adhere to the mutual acceptance of data (MAD) under OECD Council Decision C(97)114/Final, including Brazil, India, Malaysia, Singapore, and South Africa, as well as Argentina for industrial chemicals, pesticides, and biocides only. In June 2004, the US FDA published a comparison chart of FDA and EPA Good Laboratory Practice (GLP) regulations alongside OECD Principles for GLP, aiding in understanding the key differences and similarities in GLP standards across these regulatory bodies. Note, unlike many countries, the US EPA names its mandated use of the OECD TG, ‘the EPA Test Methods’.
Sources: en.wikipedia.org
== Career == At the institute, later Rockefeller University, he worked as an Assistant for Dr. D.W. Woolley on a dinucleotide growth factor he discovered in graduate school and on peptide growth factors that Woolley had discovered earlier. These studies led to the need for peptide synthesis and, eventually, to the idea for solid phase peptide synthesis (SPPS) in 1959. In 1963, he was sole author of a classic paper in the Journal of the American Chemical Society in which he reported a method he called "solid phase peptide synthesis". This article is the fifth most cited paper in the journal's history. In the mid-60s Dr. Merrifield's laboratory first synthesized bradykinin, angiotensin, desamino-oxytocin and insulin. In 1969, he and his colleague Bernd Gutte announced the first synthesis of the enzyme ribonuclease A. This work proved the chemical nature of enzymes. Dr. Merrifield's method greatly stimulated progress in biochemistry, pharmacology and medicine, making possible the systematic exploration of the structural basis of the activities of enzymes, hormones and antibodies. The development and applications of the technique continued to occupy his laboratory, where he remained active at the bench until recently. In 1993, Jeffrey I. Seeman published Life during a Golden Age of Peptide Chemistry, Merrifield's autobiography, in the series "Profiles, Pathways, and Dreams" for the American Chemical Society. He received the Association of Biomolecular Resource Facilities Award for outstanding contributions to Biomolecular Technologies in 1998.
Alamosaurus) as a biostratigraphic marker of the Hall Lake Formation fauna makes the dating problematic due to the fossil having a huge variability in assumed sedimentation rates. The study also suggested the uncertainty in the morphology of T. mcraeensis holotype being reliably outside the known variation of T. rex. Regardless of the age and validity of T. mcraeensis, the authors concluded that the genus Tyrannosaurus still most likely originated from Laramidia and that the ancestors of this genus possibly migrated from Asia. Later that year, Voris and colleagues regarded T. mcraeensis as a junior synonym of T. rex, agreeing with the problematic stratigraphic data and finding all of the proposed diagnostic characters of T. mcraeensis to be in the known T. rex specimen range of variation. In his study of the T. rex holotype skull, Carr also did not regard T. mcraeensis as a valid species, agreeing with the proposed characters of the T. mcraeensis holotype being visible throughout the hypodigm of T. rex.
This helps reduce the potential for deviating from the prescriber's intended use relative to buprenorphine, though it does not eradicate it. One reason that naloxone might have limited efficacy as an abuse-deterrent is that buprenorphine binds more tightly to the mu-opioid receptor than naloxone.
In November 2021, the US FDA approved pembrolizumab for the adjuvant treatment of people twelve years of age and older with stage IIB or IIC melanoma following complete resection. In November 2021, the US FDA approved pembrolizumab for the adjuvant treatment of renal cell carcinoma for people at intermediate-high or high risk of recurrence following nephrectomy. Approval was based on KEYNOTE-564, a multicenter, randomized (1:1), double-blind, placebo-controlled trial in 994 participants with intermediate-high or high risk of recurrence of RCC, or M1 no evidence of disease. In March 2022, the US FDA approved pembrolizumab for the treatment of advanced endometrial cancer. In January 2023, the US FDA approved pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥ 4 cm), II, or IIIA non-small cell lung cancer. In October 2023, the US FDA approved pembrolizumab to be used with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer. In January 2024, the US FDA approved pembrolizumab, in combination with chemoradiotherapy for the treatment of people with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. In June 2024, the US FDA approved pembrolizumab with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adults with primary advanced or recurrent endometrial carcinoma.
== Advantages == Intermediate moisture foods utilize hurdle technology by lowering water activity, reducing pH and using preservatives. Most bacteria do not grow under a water activity of 0.90 and IMF processing methods reduce water activity to 0.60-0.84. IMFs are often ready-to-eat and do not require refrigeration. This is especially important in countries with tropical climates and minimal storage and processing capacities. Nitrites and sulfites are added to food to prolong shelf life and delay flavor and color changes. Propylene glycol reduces water activity and acts as a plasticizing agent to give food its desired texture. Compared to canning, dehydration, and freezing, IMF food processing is less rigorous and results in less nutrient loss. This is because compared to other processing techniques, IMF processes are at lower temperatures, pressures, and there is no water leaching of nutrients. Additionally, IMF production is more energy efficient compared to conventional processes including canning and freezing since IMFs do not require refrigeration. The energy required for canning and freezing is costly, thus IMF are common in developing countries.
Sources: en.wikipedia.org
The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.
Lyophilized powder is usually kept frozen and protected from moisture. Solutions are less stable and are often used promptly or divided into aliquots to avoid repeated freeze-thaw cycles. Exact shelf-life values depend on purity and handling.
No. A purity figure derived from chromatographic area does not prove the amino acid sequence. Identity requires an orthogonal method such as mass spectrometry or sequencing. Truncated or isomerized peptides can co-elute with the target compound.
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.